Automate Your Wheel Strategy on TEM
With Tiblio's Option Bot, you can configure your own wheel strategy including TEM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TEM
- Rev/Share 5.4907
- Book/Share 1.7854
- PB 47.5624
- Debt/Equity 2.7563
- CurrentRatio 1.5406
- ROIC -0.1583
- MktCap 14324625663.0
- FreeCF/Share -0.4017
- PFCF -205.6954
- PE -73.7156
- Debt/Assets 0.525
- DivYield 0
- ROE -1.0712
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | TEM | TD Cowen | Buy | Hold | -- | $88 | Oct. 21, 2025 |
| Initiation | TEM | Canaccord Genuity | -- | Buy | -- | $110 | Oct. 20, 2025 |
| Initiation | TEM | H.C. Wainwright | -- | Buy | -- | $90 | Sept. 2, 2025 |
| Initiation | TEM | BTIG Research | -- | Buy | -- | $60 | April 21, 2025 |
| Downgrade | TEM | JP Morgan | Overweight | Neutral | $50 | $55 | Feb. 25, 2025 |
| Downgrade | TEM | William Blair | Outperform | Market Perform | -- | -- | Feb. 12, 2025 |
| Resumed | TEM | TD Cowen | -- | Buy | $58 | $74 | Feb. 5, 2025 |
| Initiation | TEM | Wolfe Research | -- | Outperform | -- | $60 | Dec. 13, 2024 |
| Initiation | TEM | Guggenheim | -- | Buy | -- | $74 | Dec. 9, 2024 |
| Downgrade | TEM | BofA Securities | Buy | Neutral | $45 | $60 | Oct. 2, 2024 |
News
Tempus to Report Third Quarter 2025 Financial Results on November 4
Published: October 21, 2025 by: Business Wire
Sentiment: Neutral
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter of 2025 on November 4, 2025. The company will hold the earnings conference call at 4:30 pm ET. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Altern.
Read More
Tempus AI Stock Before Q3 Earnings Release: To Buy or Not to Buy?
Published: October 20, 2025 by: Zacks Investment Research
Sentiment: Positive
TEM's 48% surge, key FDA clearances and bold AI acquisitions set the stage for its Q3 earnings reveal.
Read More
Tempus AI Fuels Growth Through Strategic Biotech Collaborations
Published: October 17, 2025 by: Zacks Investment Research
Sentiment: Positive
TEM expands its AI-driven growth with new collaborations in oncology, neurogenomics, and diagnostic innovation.
Read More
Tempus AI Hits $100—Are Shares Due for a Pullback?
Published: October 15, 2025 by: MarketBeat
Sentiment: Positive
Tempus AI NASDAQ: TEM has been publicly traded for only 16 months, and it has been nothing short of a market standout over that time. Compared to its IPO price of $37, Tempus shares were up by a whopping 155% on Monday, Oct. 13.
Read More
TEM Expands Partnership With Northwestern Medicine Amid AI Boom
Published: October 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Tempus AI deepens its collaboration with Northwestern Medicine, embedding its AI co-pilot David directly into the health system's EHR to boost clinical efficiency.
Read More
Strategic Deals Drive TEM Growth Amid Competition: Buy, Hold or Sell?
Published: October 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Tempus AI sharpens its edge in precision medicine with key acquisitions, strong R&D launches, and improving financials amid rising competition.
Read More
Ambry Genetics Announces Improved EHR-Integrated Breast Cancer Risk Assessment Solution with Upgraded Tyrer-Cuzick Scoring Approach Incorporating Breast Density
Published: October 01, 2025 by: Business Wire
Sentiment: Neutral
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics Announces Improved EHR-Integrated Breast Cancer Risk Assessment Solution.
Read More
TEM vs. ILMN: Which Precision Oncology Stock Is Worth Buying Now?
Published: September 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors are showing growing interest in the rapidly expanding Precision Oncology market, which is expected to witness a compound annual growth rate (CAGR) of 8% between 2025 and 2030, according to Grand View Research. Tempus AI TEM and Illumina ILMN are two key players with significant presence in this market.
Read More
Tempus AI Enhances Cancer Research Tools With FDA-Cleared xR IVD
Published: September 23, 2025 by: Zacks Investment Research
Sentiment: Positive
TEM secures FDA clearance for its xR IVD device, advancing RNA-based cancer research and precision medicine tools.
Read More
Kuehn Law Encourages Investors of Tempus AI, Inc. to Contact Law Firm
Published: September 19, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Sept. 19, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Tempus AI, Inc. (NASDAQ: TEM) breached their fiduciary duties to shareholders.
Read More
TEM Strengthens Radiology Portfolio With Pixel's FDA Clearance
Published: September 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Tempus AI secures FDA clearance for its updated Pixel cardiac imaging platform, boosting radiology precision and efficiency.
Read More
Tempus (TEM) Stock Jumps 13.6%: Will It Continue to Soar?
Published: September 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Tempus (TEM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Read More
TEM Gains Validation for PurIST Amid Evolving Cancer Care Landscape
Published: September 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Tempus AI's PurIST test secures clinical validation, helping personalize treatment choices for advanced pancreatic cancer patients.
Read More
TEM Q2 Revenues Soar Amid Coverage Issues: Time to Buy, Hold or Sell?
Published: September 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Tempus AI TEM posted robust second-quarter results and raised the sales guidance for 2025 for the second time within six months. Full-year revenues are now expected to be approximately $1.26 billion (earlier $1.25 billion), indicating nearly 82% annual growth.
Read More
Tempus AI: Expansive Opportunity As Healthcare Becomes More Heavily Scrutinized
Published: September 04, 2025 by: Seeking Alpha
Sentiment: Positive
Tempus AI, Inc. is positioned for growth as U.S. pharmaceutical reshoring and regulatory scrutiny increase demand for data-driven healthcare services. Genomics and Data Services segments are experiencing rapid revenue and margin expansion, bolstered by robust test volume growth. The Paige AI acquisition can add to the momentum. Financially, Tempus is nearing adjusted EBITDA breakeven, has strengthened its balance sheet with convertible notes, and managed dilution risk with capped calls.
Read More
What's Fueling Tempus AI's Q2 Net Loss Improvement Momentum?
Published: September 04, 2025 by: Zacks Investment Research
Sentiment: Positive
TEM's Q2 net loss narrows sharply, driven by surging genomics revenues, higher gross profits and tighter cost controls.
Read More
Tempus' Key Acquisitions Strengthen Its AI Healthcare Leadership
Published: August 26, 2025 by: Zacks Investment Research
Sentiment: Positive
TEM accelerates its healthcare edge with Paige, Deep 6 AI, and Ambry Genetics acquisitions, expanding data, tech and clinical reach.
Read More
Tempus AI or Butterfly: Which AI Health Tech Stock is a Buy Now?
Published: August 25, 2025 by: Zacks Investment Research
Sentiment: Positive
BFLY trades at distressed levels with analyst targets signaling sharp upside, while TEM's premium valuation tempers its appeal.
Read More
4 Medical Devices Behemoths to Buy Amid Extensive AI Applications
Published: August 22, 2025 by: Zacks Investment Research
Sentiment: Positive
AI-driven innovations in medical devices are fueling growth for BSX, JNJ, GEHC and TEM.
Read More
5 High Short-Interest Stocks to Buy Before November
Published: August 20, 2025 by: MarketBeat
Sentiment: Positive
This is a look at five stocks to consider buying before November. No, there isn't a major election cycle, but these high short-interest names have bullish market fundamentals and are expected to report their Q3 results in November.
Read More
Strategic Partnerships Power Tempus AI's Healthcare Expansion
Published: August 19, 2025 by: Zacks Investment Research
Sentiment: Positive
TEM deepens collaborations in oncology and neuroscience using its Lens and Next platforms to accelerate precision medicine.
Read More
Tempus AI: TEM Stock To $130?
Published: August 18, 2025 by: Forbes
Sentiment: Positive
Tempus AI (NASDAQ: TEM) has already posted a strong 2x gain since its IPO, rising from $37 to $74. Although it trades at a lofty 14x trailing revenue multiple, the company's solid growth trajectory and expanding market opportunity indicate room for continued upside, as outlined below.
Read More
TEM Once Again Raises Its 2025 Sales Guidance: What's Driving the Move?
Published: August 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Tempus AI raises 2025 revenue outlook again after strong Q2 growth in genomics and AI-driven oncology solutions.
Read More
TEMPUS FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Tempus Investors of the August 11th Deadline and Urges Investors to Contact the Firm
Published: August 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
Bragar Eagel & Squire, P.C. Litigation Attorneys Encourage Investors Who Suffered Losses In Tempus (TEM) To Contact Him Directly To Discuss Their Options
Read More
Tempus AI: Buy or Sell TEM Stock At $65?
Published: August 11, 2025 by: Forbes
Sentiment: Positive
Tempus AI stock has increased by 10% over the past week, fueled by impressive quarterly results and a raised sales forecast for the entire year. The company is now predicting an 82% year-over-year increase in sales, amounting to approximately $126 million.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Tempus AI, Inc. of Class Action Lawsuit and Upcoming Deadlines - TEM
Published: August 11, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Aug. 11, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Tempus AI, Inc. ("Tempus" or the "Company")(NASDAQ: TEM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
INVESTOR DEADLINE TOMORROW: Robbins Geller Rudman & Dowd LLP Announces that Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - TEM
Published: August 11, 2025 by: PRNewsWire
Sentiment: Neutral
SAN DIEGO , Aug. 11, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, both dates inclusive (the "Class Period"), have until this upcoming Tuesday, August 12, 2025 to seek appointment as lead plaintiff of the Tempus AI class action lawsuit. Captioned Shouse v.
Read More
TEM Securities Lawsuit Filed Against Tempus AI, Inc. Contact the DJS Law Group to Discuss Your Rights
Published: August 11, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , Aug. 11, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Tempus AI, Inc. ("Tempus" or "the Company") (NASDAQ: TEM) for violations of securities laws. Shareholders who purchased the Company's securities between August 6, 2024, and May 27, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before August 12, 2025.
Read More
TEM Investors Have Opportunity to Lead Tempus AI, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: August 11, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , Aug. 11, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Tempus AI, Inc. ("Tempus" or "the Company") (NASDAQ: TEM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 6, 2024 and May 27, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before August 12, 2025.
Read More
Deadline Soon: Tempus AI, Inc. (TEM) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
Published: August 08, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming August 12, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, inclusive (the “Class Period”). IF YOU ARE AN INVESTOR WHO LOST MONEY ON TEMPUS AI, INC. (TEM), CLICK HERE TO PARTICIPATE IN THE SECURITIES FRA.
Read More
About Tempus AI, Inc. (TEM)
- IPO Date 2024-06-14
- Website https://www.tempus.com
- Industry Medical - Healthcare Information Services
- CEO Eric P. Lefkofsky
- Employees 2400